Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects.
about
Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patientsUsing internet enabled mobile devices and social networking technologies to promote exercise as an intervention for young first episode psychosis patients.Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health AdministrationGenetic associations of brain structural networks in schizophrenia: a preliminary studyAlmost all antipsychotics result in weight gain: a meta-analysis.The association between antipsychotic agents and the risk of myocardial infarction: a systematic review.An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia.A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controlsMetabolic syndrome and bipolar disorder: what should psychiatrists know?Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.Diabetes mellitus and severe mental illness: mechanisms and clinical implications.Implementing and maintaining nurse-led healthy living programs in forensic inpatient settings: an illustrative case study.Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis.Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis.Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics.Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder
P2860
Q27027832-B823AA56-C0B2-4953-ADB6-4127416FDA87Q30501289-B5697849-E9BD-4054-8640-D0ED0AACB48AQ33519730-5F1D8E39-8FE6-4F61-B22D-3A1764BEAD85Q34343604-EB31673D-AECE-4EDB-B424-6F80F4DD9DD6Q34661499-8C2FC635-F456-419B-B4EF-B46E8A074A74Q35629735-69B0C4BD-1B45-4EED-8CC1-4E8F8A211404Q37062558-F046BD85-AF4F-4F23-8524-A4B49427C3F8Q37236162-63625C7B-6D71-4ADA-9B05-E38144E0D2B5Q37954425-D4B290FB-7B7F-4166-AC17-1A4029820E44Q38209971-ABC81F0D-FCBD-4D8D-B7B3-F85D6A99A755Q38274901-4F90DC0B-50C0-4CFA-9DE0-C32CCFBA32F7Q39740943-1A1CDFC1-7721-42A7-B649-D702458660A5Q52755746-3680CFE3-0E5D-4F7A-9FD3-C50182A00D49Q55241644-411EE037-34FE-4D62-BFB1-362DC3E08FB5Q55397191-59D6414E-4910-4782-AAD5-AC4A66CB4BF5Q59131843-B4193ECD-8C3E-459E-BE68-646D751B528E
P2860
Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Early treatment-related change ...... st episode psychosis subjects.
@ast
Early treatment-related change ...... st episode psychosis subjects.
@en
type
label
Early treatment-related change ...... st episode psychosis subjects.
@ast
Early treatment-related change ...... st episode psychosis subjects.
@en
prefLabel
Early treatment-related change ...... st episode psychosis subjects.
@ast
Early treatment-related change ...... st episode psychosis subjects.
@en
P2093
P2860
P1476
Early treatment-related change ...... st episode psychosis subjects.
@en
P2093
Hyunsoon Cho
Joyce B Harp
Karen A Graham
Kimberly A Brownley
P2860
P304
P356
10.1016/J.SCHRES.2007.12.476
P407
P577
2008-02-05T00:00:00Z